PharmaShots’ Key Highlights of Fourth Quarter 2023

Shots: The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1B The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…

BySenior EditorJanuary 16, 2024

INSIGHTS+

J.P. Morgan Special: Dealmaker of the Year 2023 (Part 02)

Shots: In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B Propelled by the invaluable…

BySenior EditorJanuary 15, 2024

INSIGHTS+

Disease of the Month – Glioblastoma

Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved For the January edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Glioblastoma, the most…

BySenior EditorJanuary 11, 2024

INSIGHTS+

Insights+ Key Biosimilars Events of December 2023

Shots: Stay up to date with PharmaShots Biosimilars Report, a monthly digest designed to keep you familiarized with the recent developments in biologics Biosimilars are cost-effective alternatives to branded drugs but are very much alike when it comes to safety and efficacy Check out the developments in the Biosimilars with PharmaShots’ illuminating report. PharmaShots has…

BySenior EditorJanuary 9, 2024

INSIGHTS+

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)

Shots: As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01) The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases Propelled by the invaluable…

BySenior EditorJanuary 4, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in November 2023

Shots: The EMA approved 3 BLA while 6 New Chemical Entities with 1 recommendation and 1 acceptance in November 2023, leading to treatments for patients and advances in the healthcare industry In November 2023, the major highlighted drugs were Vyjuvek to Treat Dystrophic Epidermolysis Bullosa (DEB) and Vyvgart with Halozyme’s Enhanze for the treatment of…

BySenior EditorDecember 29, 2023

INSIGHTS+

Top Performing Drug – Xtandi (December Edition)

Shots: In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Xtandi and prepared a curated analysis report for our readers Xtandi is indicated for the treatment of certain prostate cancers PharmaShots presents a concise take on the key features of Xtandi with…

BySenior EditorDecember 28, 2023

INSIGHTS+

New Drug Designations – November 2023

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EMA and China. This month’s report includes 3 biological drugs, 12 small molecules, 13 cell and gene therapies, 1 peptide, 3 exosome-based therapy and 4 devices Atsena Therapeutics’ capsid AAV.SPR gene therapy, focused on the treatment of Leber congenital…

BySenior EditorDecember 27, 2023

INSIGHTS+

Know Your Investor: Google Ventures

Shots: An investment arm of Alphabet Inc., Google Ventures Management Company colossally in seed stage companies, in diverse fields ranging from software and internet to healthcare, life sciences, and artificial intelligence among others Since 2016, GV has shifted its focus from seed-stage companies to evolved companies. With over $8B worth of assets under the management…

BySenior EditorDecember 27, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2023

Shots: The US FDA approved 5 NDAs & 4 BLAs in November 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023 In November 2023, the major highlights drugs were Wezlana (ustekinumab) approved for Multiple Inflammatory Diseases, and Cosentyx (secukinumab) for the Treatment…

BySenior EditorDecember 20, 2023

Senior Editor

PharmaShots’ Key Highlights of Fourth Quarter 2023

J.P. Morgan Special: Dealmaker of the Year 2023 (Part 02)

Disease of the Month – Glioblastoma

Insights+ Key Biosimilars Events of December 2023

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)

Insights+: EMA Marketing Authorization of New Drugs in November 2023

Top Performing Drug – Xtandi (December Edition)

New Drug Designations – November 2023

Know Your Investor: Google Ventures

Insights+: The US FDA New Drug Approvals in November 2023

Contact US

FOLLOW US